To examine the performance of a primary magnetic resonance imaging (MRI)/ultrasonography (US) fusion-guided targeted biopsy (TB), and in combination with an added systematic biopsy (SB).
Introduction
The introduction of multiparametric MRI (mpMRI) of the prostate to the diagnostic pathway of prostate cancer has greatly influenced clinical practice in recent years. In particular, for men with previously negative biopsies, performing mpMRI before a repeat biopsy has been integrated as an option into the current guidelines of the European Association of Urology (EAU), Germany, and the National Institute for Health and Care Excellence (NICE) [1] [2] [3] . This was based on many positive studies showing that the mpMRI pathway followed by a MRI/US fusion-guided targeted biopsy (TB) increased the overall detection rate compared to a systematic biopsy (SB) and especially improved the rate of diagnosed clinically significant prostate cancer [4] [5] [6] . For performing mpMRI before a primary biopsy, there is either no statement (NICE guidelines) or a statement against the use of primary mpMRI (German guideline) [1, 3] . The current EAU guideline expresses the diverging evidence of a primary mpMRI at the time of the guideline assessment and therefore does not recommend its use [2] . The skepticism about using mpMRI, as a tool in detecting significant prostate cancer, at initial biopsy may change after the publication of the PROstate MRI Imaging Study (PROMIS), which clearly showed improved patient selection for an initial prostate biopsy by mpMRI compared to a TRUS-guided biopsy [7] . The PROMIS study did not include TBs, as for a highly accurate reference a template prostate mapping (TPM) biopsy was performed. Yet, an equal performance of TPM and TB was suggested.
In the present study, we therefore evaluated the performance of a primary MRI/US fusion-guided TB for the detection of clinically significant prostate cancer.
Patients and Methods

Study Population
In this retrospective analysis, all 318 consecutive patients received a sensor-based, real-time MRI/US fusion-guided transrectal TB combined with a TRUS-guided 10-core SB of the prostate. Patients were examined between January 2012 and December 2016 at the Charit e -Universit€ atsmedizin Berlin. The inclusion criteria were: no previous biopsy of the prostate and at least one suspicious lesion of the prostate according to the Prostate Imaging Reporting and Data System (PI-RADS) classification in mpMRI defined as PI-RADS ≥3. As of September 2015, all mpMRI lesions were rated according to PI-RADS version 2. Indications to perform mpMRI were an elevated PSA level and/or a suspicious DRE. The MRI was requested by the treating urologist based on the patients' parameters and patients were admitted to our hospital only if PI-RADS ≥3 lesions were present. Patient meta-data were collected in accordance with the Standards of reporting for MRI-targeted biopsy studies (START) checklist in a prospective database [8] . Subgroups of this cohort were included in previous analyses [9, 10] . All patients signed a written informed consent for the intervention, data acquisition, and data appraisal. The study was performed according to the Declaration of Helsinki and authorised by the Institutional Review Board of the Charit eUniversit€ atsmedizin Berlin.
mpMRI Protocol
All patients received a 3-T mpMRI (Magnetom Skyra; Siemens Medical Systems, Erlangen, Germany) without an endorectal coil. The MRI protocol always comprised multiplanar (axial and coronal) high spatial resolution T2-weighted turbo spin-echo sequences (T2w TSE), axial T1-weighted images, axial diffusion-weighted images (DWIs; measured b-values 0.400 and 800 s/mm 2 , calculated b-value of 1 400 s/mm 2 ) and gadolinium-based dynamic contrast-enhanced (DCE) sequences. T2w imaging and DWIs were performed in all patients and DCE MRI in most patients. In compliance with the guidelines of the European Society of Urogenital Radiology (ESUR) the evaluation and validation of the mpMRI image data were performed or supervised by experienced radiologists. Considering clinical routine, radiologists were not blinded to clinical data. For patients with multiple lesions, the maximal PI-RADS score was used for further analysis.
MRI/US Fusion-Guided TB and SB
In accordance with the EAU guidelines, the interventions were performed under antibiotic prophylaxis with a fluoroquinolone (ciprofloxacin). MRI/US fusion-guided TB of the prostate was performed first, using the high-end US machine HiVison Preirus (Hitachi Medical Systems, Tokyo, Japan) or Aplio 500 (Toshiba, Otawara, Japan) with an endocavity endfire probes (11C3, Toshiba; EUP V53 W; Hitachi Medical Systems) or a biplane probe (EUP CC531, Hitachi Medical Systems), as described previously [9] . Briefly, we used a sensor-based registration, tracking the movement of the US probe through a low magnetic field (0.1 T) and a sensor applied to the probe. After marking the lesion of the US platform's image software, the identical planes of the MRI and the US image of the prostate were fused in a rigid image fusion according to identification of anatomical landmarks (i.e. BPH nodes, intraprostatic cysts, peri-prostatic vessels, verumontanum). Both TB and SB were performed by one physician in one biopsy session. Additionally, SB was performed, as previously described, under local anaesthesia with bupivacaine injected at the dorsal prostatic capsule [9] . All cores were potted and documented separately and were examined and analysed by an experienced pathologist.
Definition of Clinically Significant Prostate Cancer
Clinically significant prostate cancer was defined as Gleason score ≥4 + 3 = 7 (International Society of Urological Pathology [ISUP] grade 3) or maximum cancer core length (MCCL) of ≥6 mm according to the PROMIS criteria [11] . Gleason scoring was based on the highest grade detected on histological analysis. Gleason scores of 7 were differentiated as 3 + 4 = 7a (ISUP grade 2) and 4 + 3 = 7b (ISUP grade 3).
Statistical Analysis
All analyses were performed using the Statistical Package for the Social Sciences (SPSS 
Results
Between January 2012 and December 2016, 318 biopsy-na€ ıve patients received a sensor-based, real-time MRI/US fusionguided TB combined with a TRUS-guided 10-core SB. Demographic data and clinical characteristics of all the men are shown in Table 1 . The mpMRI was rated according to PI-RADS version 1 in 169 cases and PI-RADS version 2 in 149. According to the mpMRI results, a median (IQR) of 1 (1-2) suspicious lesions/patient was diagnosed. A median (IQR) of 10 (10-10) systematic cores and 4 (3-4) targeted cores were taken per patient, reaching a cumulative median (IQR) number of biopsies of 14 (13) (14) per case (P < 0.005). The median (IQR) MCCL was 4 (0-9) mm for the TB and 3 (0-6) mm for the SB (P < 0.005). The PI-RADS scores were distributed as followed: PI-RADS score 3: n = 55 (17%), PI-RADS score 4: n = 154 (48%), and PI-RADS score 5: n = 109 (34%).
The overall cancer detection rate (CDR) was 77% (245/318). TB alone detected 67% (213/318) of prostate cancers and SB alone 70% (222/318). The PI-RADS subgroup analysis for CDR of TB in combination with SB, for TB alone and SB alone are shown in Fig The combination of TB and SB detected a clinically significant prostate cancer in 195 (61%) of 318 men. Based on a Gleason score ≥4 + 3 = 7b (ISUP grade 3), 137 (43%) of the 318 men had a clinically significant prostate cancer. In compliance with a MCCL ≥6 mm for Gleason score 3 + 3 = 6 and Gleason score 3 + 4 = 7a, 58 (18%) of the 318 men were classified as clinically significant.
For the TB alone, clinically significant prostate cancer was detected in 163 (51%) of 318 men. In 104 (32%) of the 318 men, a Gleason score ≥4 + 3 = 7b (ISUP grade 3) was found and in 59 (19%) the MCCL determined a clinically significant disease (Table 2) . TB alone would have missed 32 (16%) significant cancers in comparison with the results of the combination of TB and SB. Combining TB with a SB lead to an improved detection of significant prostate cancer of 10% compared to a TB-only approach. The largest difference was seen in the detection of Gleason score ≥8, where the TB alone would have missed or underestimated 31 men (10%, P < 0.001).
Additionally, we evaluated the number of significant cancers on SB alone. Clinically significant cancer on SB alone was found in 145 (46%) of the 318 men (Table 2) . SB alone would have missed or underestimated 21 men (7%, P < 0.001) with a Gleason score ≥8 in comparison with the results of the combination of SB and TB.
The detection rates of significant cancers detected on TB in combination with SB according to different definitions of clinically significant prostate cancer used by other authors are shown in Table 3 [11] [12] [13] .
The rate of insignificant prostate cancer was comparable for TB in combination with SB (50/318, 16%) and TB alone (50/318, 16%) (Fig. 2a) . The ratios of no cancer, insignificant, and significant cancer within each PI-RADS group based upon TB and SB, and TB alone are presented in Fig. 2b .
A Gleason upgrading in the SB compared to the results of the TB was detected in 32% (79/245), of which 9% (23/245) were upgraded to clinically significant prostate cancer. Conversely, the results of the TB showed a Gleason upgrading in 26% (63/245) compared to SB and upgraded in 14% (34/245) to clinically significant prostate cancer. Out of 245 patients in which prostate cancer was detected, 129 (53%) underwent radical prostatectomy, 24 (10%) radiation therapy, 14 (6%) were enrolled into active surveillance programmes, six (2%) received a focal treatment, another six (2%) were treated with LHRH-antagonists, and in 66 (27%) we had no follow-up information. (Table S1) .
Discussion
MRI has clearly demonstrated its additional value in biopsy guidance within TB due to better image resolution, superior visualisation of anatomical structures and assessment of tumour aggressiveness [14] . The PROMIS group represents Level 1b Evidence for evaluation of diagnostic accuracy of mpMRI in biopsy-na€ ıve men for the detection of clinically significant prostate cancer and suggested that if mpMRI was used as a triage test, one-quarter of men might safely avoid prostate biopsy [11] . Nonetheless, the reported results assume that TBs would achieve similar diagnostic accuracy as TPM biopsy. Hence, a limitation of PROMIS is that no MRI-guided or MRI TBs were performed. There is a reported superiority of TPM biopsy over the TRUS-guided biopsy and also a trend towards detection of clinically significant prostate cancer [15, 16] . However, TPM biopsy remains an invasive procedure under general or spinal anaesthesia with an extensive number of cores taken during biopsy. Particularly, MRI/US fusion-guided biopsy increased the detection of clinically relevant disease, whilst also decreasing the detection of low-risk cancer with a reduced number of needed cores [17, 18] . As MRI/US fusion-guided biopsy alone is currently not advised by most authors and Table 2 Gleason scores of detected significant cancers on SB in combination with TB, TB alone, and SB alone.
Total number of patients n = 318 The differences in detected significant prostate cancer between the groups are explained either by non-detection or MCCL of <6 mm for Gleason score 6 in the sole analysis for TB or SB and cancer detection, Gleason upgrading in the combined approach (TB + SB). The percentages do not add up to 100% due to rounding up. *Men classified as clinically significant in accordance with a MCCL of ≥6 mm.
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© 2018 The Authors BJU International © 2018 BJU International in the current guidelines, an additional 10-12-core SB is indicated [1, 2, 12, 19] . Consistently there is a reported superior performance of the combination of TB and SB in overall detection rate but also with an associated contamination with insignificant prostate cancer [9, 20, 21] . We therefore analysed the performance of MRI/US fusionguided biopsy in combination with a TRUS-guided SB in a biopsy-na€ ıve setting.
Our present study showed that SB alone would have missed or underestimated, especially prostate cancer with a Gleason score ≥8, in comparison with the results of the combination of SB and TB. But, consistent with previous reports and despite a superior role of TB, there still remains an indication for the traditional SB [9, 10] . Consequently, TB alone would have missed significant cancers in comparison with the results of the combination of TB and SB. Combining TB with a SB lead to an improved detection of clinically significant prostate cancer and the largest difference was seen in the detection of Gleason score ≥8. The combination of SB and TB in biopsyna€ ıve patients detected prostate cancer in 77% of men and based upon the definition of a Gleason score ≥4 + 3 = 7b (ISUP grade 3) or maximal cancer core length ≥6 mm, 61% of cases had clinically significant prostate cancer.
There is a heterogeneous use of the term 'significant prostate cancer'. The definition of clinically significant prostate cancer used within the PROMIS study is supported by statistical evidence showing a significant recurrence-free survival advantage for Gleason 3 + 4 = 7a (ISUP grade 2) compared with Gleason 4 + 3 = 7b (ISUP grade 3) in terms of predicting patient outcome after surgery for clinically localised prostate cancer [22] . Furthermore, we agree on the incorporation of the MCCL as an indicator for clinical significance, as also active surveillance is based on core involvement within in the European guidelines on prostate cancer [2] . A recently published meta-analysis investigating whether MRI-guided biopsy has increased detection rates of (clinically significant) prostate cancer compared with TRUSguided biopsy in patients at risk of prostate cancer stated as a limitation the heterogeneous usage of definitions for clinically significant prostate cancer originating mainly from the SB setting [23] . The meta-analysis reported on only three included studies that used a definition of clinically significant prostate cancer solely based on the presence of a Gleason 4 component on biopsy. However, selected patients with a Gleason score 3 + 4 = 7 could also be discussed for active surveillance, especially if the pattern 4 is limited, and in Table 3 Gleason scores of detected significant cancers on SB in combination with TB shown for primary, secondary, and tertiary definition of clinically significant cancer.
Total number of patients n = 318
Gleason score ≥4 + 3 or MCCL ≥6 mm (PROMIS [11] ) n (%)
Gleason score ≥3 + 4 (Borkowetz et al. [12] ) n (%)
Gleason score ≥3 + 4 or MCCL ≥5 mm (Haffner et al. [13] ) n (%) 21 (11) 21 (11) 21 (10) 10 3 (2) 3 (2) 3 (1) *Men classified clinically significant in accordance with a MCCL ≥6 mm. Compared with detection rates of recent studies investigating prostate biopsy-na€ ıve patients, our present data are in line with the results of the PROMIS study [11] . Other studies reported lower rates of significant prostate cancer. A recent study by Borkowetz et al. [12] stated a rate of clinically significant prostate cancer (defined as Gleason score ≥3 + 4) of 44% (94/214). Haffner et al. [13] , who defined significant prostate cancer as Gleason score ≥3 + 4 or MCCL ≥5 mm, reported significant prostate cancer in 45% (249/555) of biopsy-na€ ıve men. Adjusted to the different level of significance the detection in our present cohort was 61% (Gleason score ≥3 + 4) and 80% (Gleason score ≥3 + 4 or MCCL ≥5 mm). Therefore, there remains heterogeneity (even if the definition of significant prostate cancer is adjusted) within the published levels of significant prostate cancer in the primary biopsy setting. Nevertheless, the published data shows the improvement of the mpMRI pathway on diagnostic accuracy. Further, within in our present study, the rate of insignificant cancers was not increased by an additive SB in comparison to TB alone.
Within in the literature there is an ongoing discussion regarding the incorporation of MRI and TB into practice guidelines for prostate cancer, which are mostly based on cost-effectiveness, especially in biopsy-na€ ıve men [26] [27] [28] . Not only the elevated risk of bleeding and sepsis and an associated prolonged healthcare contact, but also the detection of indolent cancers and consecutive aggressive treatments may lead to intensified costs related to the standard biopsy setting for the detection of prostate cancer [29, 30] . A recent analysis showed that diagnostic MRI for the initial detection of prostate cancer can be cost-effective compared with the standard TRUS-guided SB strategy in the USA [31] .
As only lesions with PI-RADS scores ≥3 were included and further biopsied, mpMRI was indirectly used as a diagnostic screening tool. Patients with no lesions visible on mpMRI were not included. The reported negative predictive value of the mpMRI was 83% for any prostate cancer and 98% for Gleason score ≥7 [32] . The PROMIS study showed a negative predictive value of 89% for clinically significant prostate cancer [11] . Hence, we believe that the inclusion of patients with lesions with PI-RADS scores of 1 or 2 would not have changed the study significantly. Although there are studies reporting a limited utility of the standard biopsy in addition to TB [17, 23] , other authors conclude that TB should be combined with SB for improved detection of clinically significant prostate cancer [12, 33] . Therefore, our intention was not to compare TB with SB, but to evaluate the combination of TB and SB for primary biopsy. To our knowledge, the current number of randomised controlled trials performing a direct comparison in a primary biopsy setting is limited, but the PRECISION trial (PRostate Evaluation for Clinically Important Disease: Sampling Using Image-guidance Or Not? NCT02380027) might give a clearer answer to such a question.
Despite a positive role of MRI/US fusion-guided biopsy in biopsy-na€ ıve patients, we acknowledge limitations to the present study. Primarily, our present study represents a single centre analysis without randomisation, whereas multicentre randomised trials are desirable. On the other hand, our series presents a real-life cohort, where the indication for mpMRI and TBs was given by the treating urologist, who then admitted the patient to the hospital only if a suspicious lesion was present. Due to the same urologist performing the 10-core SB subsequent to the MRI/US fusion-guided biopsy, the MRI pre-detected lesion was very likely re-biopsied with a consecutive bias to the result of the SB. However, there are data indicating that saturation of the index lesion may significantly decrease the risk of Gleason upgrading at radical prostatectomy [34] .
In general, a major concern is the comparability of the PROMIS results to daily clinical practice. First, there are to our knowledge no comparative studies between TPM biopsy and transrectal TB. Second, as there are no recommended settings for targeted strategies (transrectal vs transperineal; MRI in-bore guided vs MRI/US fusion-guided) each study includes individual approaches. Third, the quality of mpMRI scans and reports can differ massively between medical centres due to a lack of standardisation in protocols and different levels of reader experience, where PROMIS only performed scans after centralised and repeated training of involved radiologists [35, 36] . Thus, the data derived from the PROMIS study may be positively influenced and this should be taken into account during interpretation.
Acknowledging the substantial work of the PROMIS group, we herewith provide data from a study that may highlight the value of mpMRI for early prostate cancer detection in a realworld setting. In addition, our present results show the advantage of MRI/US fusion in biopsy targeting, but even more importantly the relevance of a subsequent SB in order to further improve the detection of clinically significant disease.
Conclusion
In conclusion, our present findings underline the incremental value of pre-biopsy mpMRI to increase the detection of clinically significant prostate cancer in biopsy-na€ ıve patients with suspicion of prostate cancer. Combining MRI/US fusionguided TB with a SB further improved the diagnostic 216 © 2018 The Authors BJU International © 2018 BJU International accuracy without increasing the rate of insignificant prostate cancer.
